Original articles
Kuan Hu, Wenyu Wu, Lin Xie, Hao Geng, Yiding Zhang, Masayuki Hanyu, Lulu Zhang, Yinghuan Liu, Kotaro Nagatsu, Hisashi Suzuki, Jialin Guo, Yundong Wu, Zigang Li, Feng Wang, Mingrong Zhang. Whole-body PET tracking of a d-dodecapeptide and its radiotheranostic potential for PD-L1 overexpressing tumors[J]. Acta Pharmaceutica Sinica B, 2022, 12(3): 1363-1376

Whole-body PET tracking of a d-dodecapeptide and its radiotheranostic potential for PD-L1 overexpressing tumors
Kuan Hua, Wenyu Wub, Lin Xiea, Hao Gengc, Yiding Zhanga, Masayuki Hanyua, Lulu Zhanga, Yinghuan Liuc, Kotaro Nagatsua, Hisashi Suzukia, Jialin Guof, Yundong Wuc,e, Zigang Lic,d, Feng Wangb, Mingrong Zhanga
a. Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan;
b. Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China;
c. State Key Laboratory of Chemical Oncogenomics, the School of Chemical Biology and Biotechnology, Peking University, Shenzhen Graduate School, Shenzhen 518055, China;
d. Pingshan Translational Medicine Center, Shenzhen Bay Laboratory, Shenzhen 518118, China;
e. Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen 518038, China;
f. Rensselaer Polytechnic Institute, Troy, NY 12180, USA
Abstract:
Peptides that are composed of dextrorotary (d)-amino acids have gained increasing attention as a potential therapeutic class. However, our understanding of the in vivo fate of d-peptides is limited. This highlights the need for whole-body, quantitative tracking of d-peptides to better understand how they interact with the living body. Here, we used mouse models to track the movement of a programmed death-ligand 1 (PD-L1)-targeting d-dodecapeptide antagonist (DPA) using positron emission tomography (PET). More specifically, we profiled the metabolic routes of[64Cu]DPA and investigated the tumor engagement of[64Cu/68Ga]DPA in mouse models. Our results revealed that intact[64Cu/68Ga]DPA was primarily eliminated by the kidneys and had a notable accumulation in tumors. Moreover, a single dose of[64Cu]DPA effectively delayed tumor growth and improved the survival of mice. Collectively, these results not only deepen our knowledge of the in vivo fate of d-peptides, but also underscore the utility of d-peptides as radiopharmaceuticals.
Key words:    d-peptide    PET imaging    Radiotheranostics    In vivo fate    PD-L1   
Received: 2021-07-13     Revised: 2021-09-02
DOI: 10.1016/j.apsb.2021.09.016
Funds: We thank the staff of the National Institutes for Quantum and Radiological Sciences and Technology (QST) for their support in cyclotron operation, radioisotope production, radiosynthesis, and animal experiments. We sincerely thank the financial support from the JSPS KAKENHI grant Nos. 19K17156, 21H02873, 21K07659, and 20H03635, Japan. This research is also supported by QST President's Strategic Grant (Exploratory Research, Japan). We also thank the financial support from the National Natural Science Foundation of China (82003532), General Project of Science and Technology Development Fund of Nanjing Medical University (NMUB2019154, China), the second round of Nanjing Clinical Medical Center "Nanjing Nuclear Medicine Center", and the China Postdoctoral Science Foundation (2019M650302).
Corresponding author: Yundong Wu,E-mai:wuyd@pkusz.edu.cn;Zigang Li,E-mai:lizg@pkusz.edu.cn;Feng Wang,E-mai:fengwangcn@hotmail.com;Mingrong Zhang,E-mai:zhang.ming-rong@qst.go.jp     Email:wuyd@pkusz.edu.cn;lizg@pkusz.edu.cn;fengwangcn@hotmail.com;zhang.ming-rong@qst.go.jp
Author description:
Service
PDF(KB) Free
Print
0
Authors
Kuan Hu
Wenyu Wu
Lin Xie
Hao Geng
Yiding Zhang
Masayuki Hanyu
Lulu Zhang
Yinghuan Liu
Kotaro Nagatsu
Hisashi Suzuki
Jialin Guo
Yundong Wu
Zigang Li
Feng Wang
Mingrong Zhang

References:
[1] Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today 2015;20:122-128
[2] Lau J L, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem 2018;26:2700-2707
[3] Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov 2020;19:277-289
[4] Otvos L, Wade JD. Current challenges in peptide-based drug discovery. Front Chem 2014;2:62
[5] Tugyi R, Uray K, Ivan D, Fellinger E, Perkins A, Hudecz F. Partial D-amino acid substitution: improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide. Proc Natl Acad Sci U S A 2005;102:413-418
[6] Chorev M. The partial retro-inverso modification: a road traveled together. Biopolymers 2005;80:67-84
[7] Fletcher MD, Campbell MM. Partially modified retro-inverso peptides:  development, synthesis, and conformational behavior. Chem Rev 1998;98:763-796
[8] Uppalapati M, Lee DJ, Mandal K, Li H, Miranda LP, Lowitz J, et al. A potent D-protein antagonist of VEGF-A is nonimmunogenic, metabolically stable, and longer-circulating in vivo. ACS Chem Biol 2016;11:1058-1065
[9] Garton M, Nim S, Stone TA, Wang KE, Deber CM, Kim PM. Method to generate highly stable D-amino acid analogs of bioactive helical peptides using a mirror image of the entire PDB. Proc Natl Acad Sci U S A 2018;115:1505-1510
[10] Rabideau AE, Pentelute BL. A D-amino acid at the N-terminus of a protein abrogates its degradation by the N-end rule pathway. ACS Cent Sci 2015;1:423-430
[11] Jia F, Wang J, Peng J, Zhao P, Kong Z, Wang K, et al. D-amino acid substitution enhances the stability of antimicrobial peptide polybia-CP. Acta Biochim Biophys Sin 2017;49:916-925
[12] Carmona G, Rodriguez A, Juarez D, Corzo G, Villegas E. Improved protease stability of the antimicrobial peptide Pin2 substituted with D-amino acids. Protein J 2013;32:456-466
[13] Feng Z, Xu B. Inspiration from the mirror: D-amino acid containing peptides in biomedical approaches. Biomol Concepts 2016;7:179-187
[14] Lau YH, de Andrade P, Wu Y, Spring DR. Peptide stapling techniques based on different macrocyclisation chemistries. Chem Soc Rev 2015;44:91-102
[15] White CJ, Yudin AK. Contemporary strategies for peptide macrocyclization. Nat Chem 2011;3:509-524
[16] Appella DH, Christianson LA, Karle IL, Powell DR, Gellman SH. β-Peptide foldamers:  robust helix formation in a new family of β-amino acid oligomers. J Am Chem Soc 1996;118:13071-13072
[17] Qvit N, Rubin SJS, Urban TJ, Mochly-Rosen D, Gross ER. Peptidomimetic therapeutics: scientific approaches and opportunities. Drug Discov Today 2017;22:454-462
[18] Schumacher TNM, Mayr LM, Minor DL, Milhollen MA, Burgess MW, Kim PS. Identification of D-peptide ligands through mirror-image phage display. Science 1996;271:1854-1857
[19] Chorev M, Goodman M. A dozen years of retro-inverso peptidomimetics. Acc Chem Res 1993;26:266-273
[20] Zhou N, Luo Z, Luo J, Fan X, Cayabyab M, Hiraoka M, et al. Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derived from chemokines. J Biol Chem 2002;277:17476-17485
[21] Sakurai K, Chung HS, Kahne D. Use of a retroinverso p53 peptide as an inhibitor of MDM2. J Am Chem Soc 2004;126:16288-16289
[22] Welch BD, VanDemark AP, Heroux A, Hill CP, Kay MS. Potent D-peptide inhibitors of HIV-1 entry. Proc Natl Acad Sci U S A 2007;104:16828-16833
[23] Liu M, Li C, Pazgier M, Li C, Mao Y, Lv Y, et al. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms. Proc Natl Acad Sci U S A 2010;107:14321-14326
[24] Zhan C, Zhao L, Wei X, Wu X, Chen X, Yuan W, et al. An ultrahigh affinity D-peptide antagonist of MDM2. J Med Chem 2012;55:6237-6241
[25] Wei X, Zhan C, Chen X, Hou J, Xie C, Lu W. Retro-inverso isomer of Angiopep-2: a stable d-peptide ligand inspires brain-targeted drug delivery. Mol Pharm 2014;11:3261-3268
[26] Zhou X, Zuo C, Li W, Shi W, Zhou X, Wang H, et al. A Novel D-peptide identified by mirror-image phage display blocks TIGIT/PVR for cancer immunotherapy. Angew Chem Int Ed Engl 2020;59:15114
[27] Chang H N, Liu BY, Qi YK, Zhou Y, Chen YP, Pan KM, et al. Blocking of the PD-1/PD-L1 interaction by a D-peptide antagonist for cancer immunotherapy. Angew Chem Int Ed Engl 2015;54:11760-11764
[28] Li H, Kem DC, Zhang L, Huang B, Liles C, Benbrook A, et al. Novel retro-inverso peptide inhibitor reverses angiotensin receptor autoantibody-induced hypertension in the rabbit. Hypertension 2015;65:793-799
[29] Luo Z, Wu Q, Yang C, Wang H, He T, Wang Y, et al. A Powerful CD8+T-cell stimulating D-tetra-peptide hydrogel as a very promising vaccine adjuvant. Adv Mater 2017;29:1601776
[30] Vaissiere A, Aldrian G, Konate K, Lindberg MF, Jourdan C, Telmar A, et al. A retro-inverso cell-penetrating peptide for siRNA delivery. J Nanobiotechnol 2017;15:34
[31] Guichard G, Benkirane N, Zeder-Lutz G, van Regenmortel MH, Briand JP, Muller S. Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics. Proc Natl Acad Sci U S A 1994;91:9765-9769
[32] Wermuth J, Goodman SL, Jonczyk A, Kessler H. Stereoisomerism and biological activity of the selective and superactive αvβ3 integrin inhibitor cyclo(-RGDfV-) and its retro-inverso peptide. J Am Chem Soc 1997;119:1328-1335
[33] Kannan S, Aronica PGA, Ng S, Gek Lian DT, Frosi Y, Chee S, et al. Macrocyclization of an all-d linear alpha-helical peptide imparts cellular permeability. Chem Sci 2020;11:5577-5591
[34] Du S, Luo C, Yang G, Gao H, Wang Y, Li X, et al. Developing PEGylated reversed D-peptide as a novel HER2-targeted SPECT imaging probe for breast cancer detection. Bioconjugate Chem 2020;31:1971-1980
[35] Subramanian R, Zhu X, Kerr SJ, Esmay JD, Louie SW, Edson KZ, et al. Nonclinical pharmacokinetics, disposition, and drug-drug interaction potential of a novel D-amino acid peptide agonist of the calcium-sensing receptor AMG 416 (etelcalcetide). Drug Metab Dispos 2016;44:1319-1331
[36] Veine DM, Yao H, Stafford DR, Fay KS, Livant DL. A D-amino acid containing peptide as a potent, noncovalent inhibitor of α5β1 integrin in human prostate cancer invasion and lung colonization. Clin Exp Metastasis 2014;31:379-393
[37] Jung KO, Kim TJ, Yu J H, Rhee S, Zhao W, Ha B, et al. Whole-body tracking of single cells via positron emission tomography. Nat Biomed Eng 2020;4:835-844
[38] Fani M, Maecke H, Okarvi S. Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics 2012;2:481
[39] Liu Z, Pourghiasian M, Radtke MA, Lau J, Pan J, Dias GM, et al. An organotrifluoroborate for broadly applicable one-step 18F-labeling. Angew Chem Int Ed Engl 2014;53:11876-11880
[40] Jackson IM, Scott PJH, Thompson S. Clinical applications of radiolabeled peptides for PET. Semin Nucl Med 2017;47:493-523
[41] Hu K, Shang J, Xie L, Hanyu M, Zhang Y, Yang Z, et al. PET imaging of VEGFR with a novel 64Cu-labeled peptide. ACS Omega 2020;5:8508-8514
[42] Hu K, Xie L, Hanyu M, Zhang Y, Li L, Ma X, et al. Harnessing the PD-L1 interface peptide for positron emission tomography imaging of the PD-1 immune checkpoint. RSC Chem Biol 2020;1:214-224
[43] Hu K, Hanyu M, Xie L, Zhang Y, Nagatsu K, Suzuki H, et al. Correction: developing native peptide-based radiotracers for PD-L1 PET imaging and improving imaging contrast by pegylation. Chem Commun 2019;55:4273
[44] Adessi C, Soto C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr Med Chem 2002;9:963-978
[45] Bullock BN, Jochim AL, Arora PS. Assessing helical protein interfaces for inhibitor design. J Am Chem Soc 2011;133:14220-14223
[46] Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Canc Therapeut 2015;14:847-856
[47] Stangl S, Tei L, De Rose F, Reder S, Martinelli J, Sievert W, et al. Preclinical evaluation of the Hsp70 peptide tracer TPP-PEG24-DFO[(89)Zr] for tumor-specific PET/CT imaging. Cancer Res 2018;78:6268-6281
[48] Miller MM, Wasik SP, Huang GL, Shiu WY, Mackay D. Relationships between octanol-water partition coefficient and aqueous solubility. Environ Sci Technol 1985;19:522-529
[49] Tencer J, Frick IM, Oquist BW, Alm P, Rippe B. Size-selectivity of the glomerular barrier to high molecular weight proteins: upper size limitations of shunt pathways. Kidney Int 1998;53:709-715
[50] Wartiovaara J, Ofverstedt LG, Khoshnoodi J, Zhang J, Makela E, Sandin S, et al. Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography. J Clin Invest 2004;114:1475-1483
[51] Wu HN, Jiang F, Wu YD. Significantly improved protein folding thermodynamics using a dispersion-corrected water model and a new residue-specific force field. J Phys Chem Lett 2017;8:3199-3205
[52] Jiang F, Wu HN, Kang W, Wu YD. Developments and applications of Coil-library-based residue-specific force fields for molecular dynamics simulations of peptides and proteins. J Chem Theor Comput 2019;15:2761-2773
[53] Qiu XY, Hu DX, Chen WQ, Chen RQ, Qian SR, Li CY, et al. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation. Biochim Biophys Acta (BBA) - Mol Basis Dis 2018;1864:1754-1769
[54] Maecke HR, Hofmann M, Haberkorn U. 68Ga-labeled peptides in tumor imaging. J Nucl Med 2005;46:172S-178S
[55] Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ, Baumann M, et al. Radiotheranostics: a roadmap for future development. Lancet Oncol 2020;21:e146-e156
[56] Sgouros G, Bodei L, McDevitt M R, Nedrow J R. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov 2020;19:589-608
[57] Jin ZH, Tsuji AB, Degardin M, Sugyo A, Obara S, Wakizaka H, et al. Radiotheranostic agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for management of peritoneal metastasis in ovarian cancer. Clin Canc Res 2020;26:6230-6241
[58] Tang C, Gomez DR, Wang H, Levy LB, Zhuang Y, Xu T, et al. Association between white blood cell count following radiation therapy with radiation pneumonitis in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2014;88:319-325
[59] Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003;2:214-221
Similar articles: